Entasis Therapeutics Holdings Inc ETTX:NASDAQ

Last Price$2.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.01(0.46%)
Bid (Size)$2.08 (50)
Ask (Size)$2.20 (2)
Day Low / High$2.18 - 2.20
Volume104.2 K
 

View Biotechnology IndustryPeer Comparison as of 06/30/2022

 

Entasis Therapeutics Holdings Inc ( NASDAQ )

Price: $2.20
Change: +0.01 (0.46%)
Volume: 104.2 K
4:00PM ET 6/30/2022
 
 

Leap Therapeutics Inc ( NASDAQ )

Price: $1.15
Change: -0.04 (3.36%)
Volume: 328.5 K
4:00PM ET 6/30/2022
 
 

Champions Oncology Inc ( NASDAQ )

Price: $8.00
Change: +0.15 (1.91%)
Volume: 5.2 K
3:56PM ET 6/30/2022
 
 

Brainstorm Cell Therapeutics Inc ( NASDAQ )

Price: $2.76
Change: -0.02 (0.72%)
Volume: 74.5 K
4:00PM ET 6/30/2022
 
 

Cue Biopharma Inc ( NASDAQ )

Price: $2.49
Change: -0.35 (12.32%)
Volume: 562.1 K
4:00PM ET 6/30/2022
 

Read more news Recent News

Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell
9:18AM ET 5/23/2022 MT Newswires

Innoviva (INVA) has entered a deal to acquire all the outstanding shares of Entasis Therapeutics Holdings (ETTX) it doesn't already own for $2.20 each in...

--Cantor Fitzgerald Downgrades Entasis Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $2 From $5
5:24AM ET 5/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Wedbush Lifts Price Target on Entasis Therapeutics Holdings to $2 From $1.80 on Innoviva's Revised Bid, Maintains Neutral Rating
6:29AM ET 4/28/2022 MT Newswires

Entasis Therapeutics Holdings (ETTX) has an average rating of outperform and price targets ranging from $1.80 to $5, according to analysts polled by...

Top Premarket Decliners
7:55AM ET 4/26/2022 MT Newswires

Protagonist Therapeutics (PTGX) shares slumped 33% after the company reported topline data from a phase 2 trial of PN-943 in ulcerative colitis. InMed...

Company Profile

Business DescriptionEntasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. View company web site for more details
Address35 Gatehouse Park Drive
Waltham, Massachusetts 02451
Phone+1.781.810.0120
Number of Employees33
Recent SEC Filing06/17/2022SC 13E3/A
President, Chief Executive Officer & DirectorManoussos Perros
VP, Chief Financial & Accounting OfficerKristie Wagner
Chief Scientific OfficerRuben Tommasi
Chief Medical OfficerDavid Altarac

Company Highlights

Price Open$2.18
Previous Close$2.19
52 Week Range$1.40 - 3.88
Market Capitalization$105.3 M
Shares Outstanding47.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.12
Beta vs. S&P 500N/A
Revenue$5.0 M
Net Profit MarginN/A
Return on Equity-145.48%

Analyst Ratings as of 06/16/2022

Buy
0
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset